ASH 2010 News Coverage

ASH 2010

Remission Rates in Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen With or Without Gemtuzumab Ozogamicin (GO): Initial Results From the Children’s Oncology Group Phase 3 Trial, AAML0531

This phase 3 study on Remission Rates in Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen With or Without Gemtuzumab Ozogamicin was recently completed by Alan S. Gamis, MD, MPH, of the Children’s Mercy Hospitals and Clinics in Kansas City, Mo., and colleagues. The findings from this study were presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Bendamustine Plus Rituximab Offers Value as Treatment Option in Patients With Lymphomas

An ongoing evaluation has shown comparable rates of secondary myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and other secondary neoplasia (sNPL) among 3 treatment regimens: bendamustine plus rituximab (B-R); cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R); and fludarabine-rituximab (F-R). The data was presented at the 52nd American Society of Hematology Meeting and Exposition.

First Prospective Randomized Study Demonstrates Safety, Efficacy of Transfusion Therapy in Adults With Sickle Cell Disease

Transfusion therapy in adults with sickle cell disease (SCD) is safe and improves or stabilizes critical laboratory markers, decreases serious sickle cell anemia-related adverse events, and decreases hospitalizations, preliminary data from the first prospective randomized study of the safety and efficacy of transfusion therapy in adults with SCD has found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

In Patients With Relapsed, Relapsed/Refractory Multiple Myeloma, Lenalidomide + Bortezomib + Dexamethasone Remains Active at >2-Year Follow-Up

Despite prior therapy with novel agents, the combination of lenalidomide, bortezomib, and dexamethasone (RVD) is very active and well tolerated in patients with relapsed and relapsed/refractory multiple myeloma after >2 years of follow-up have shown. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Role Observed for Bendamustine Plus Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

For older patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not transplant candidates or may not tolerate aggressive therapy with its associated higher toxicity, bendamustine (B) plus rituximab (R) may have a treatment role, results of an ongoing study presented at the 52nd American Society of Hematology Annual Meeting and Exposition suggest.

Rituximab Added to Aggressive Chemotherapeutic Regimens Improves Outcome of Patients With Grade 3 Follicular Lymphoma

A retrospective study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found that patients with FL-3 treated with aggressive chemotherapy regimens have improved outcomes when rituximab is added to the therapy. In fact, in the “rituximab era,” the outcome of patients with FL-3 is comparable to DLBCL, a population that also benefits from treatment with rituximab and chemotherapy, reported Philip J. Bierman, MD, University of Nebraska Medical Center, Omaha, Neb., and colleagues.

Rituximab + Vinorelbine, Ifosfamide, Mitoxantrone, and Prednisone: A Suitable Salvage Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma

The combination of rituximab plus vinorelbine, ifosfamide, mitoxantrone, and prednisone (R-NIMP) is well tolerated, yields a high complete response rate, and allows for successful mobilization of CD34+ cells in patients with diffuse large B-cell lymphoma (DLBCL) in first relapse, results of a phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.